Treatment of Idiopathic Peripheral Neuropathy

Initial Diagnostic Workup and Management

The American Diabetes Association recommends initiating first-line pharmacologic therapy with pregabalin, duloxetine, or gabapentin to manage neuropathic pain in older adults with idiopathic peripheral neuropathy, while investigating and correcting reversible causes such as vitamin B12 deficiency, hypothyroidism, and diabetes 1, 2
The American College of Physicians suggests measuring vitamin B12 with metabolites, particularly in older adults and those on metformin, as B12 deficiency is a reversible cause of neuropathy 2
The American Academy of Neurology recommends ordering serum protein electrophoresis with immunofixation to detect monoclonal gammopathies, which are an underrecognized cause of neuropathy 2
Obtaining thyroid-stimulating hormone (TSH) is recommended to identify hypothyroidism, another reversible etiology 2
A complete metabolic panel is suggested to assess for renal disease and electrolyte abnormalities 2

The American College of Cardiology recommends initiating one of three evidence-based first-line agents, pregabalin, duloxetine, or gabapentin, based on patient comorbidities and tolerability 1, 3
Duloxetine is preferred if comorbid depression is present, and provides 30-50% pain reduction and may improve numbness/tingling 1, 2, 3
Gabapentin is a cost-effective alternative, with at least 50% pain reduction observed in 38% of patients with painful diabetic peripheral neuropathy at a dose of 1200 mg daily 1

The American Academy of Neurology suggests considering tricyclic antidepressants as second-line therapy, though use caution in older adults due to anticholinergic effects 4, 5
Venlafaxine is an alternative if duloxetine is not tolerated 2
Tramadol or other opioids should be reserved for refractory cases and generally avoided due to addiction risk 4, 5

The American Geriatrics Society recommends addressing reversible factors, such as vitamin B12 deficiency, and supplementing with 2500 mcg daily if deficiency is identified 2
Optimizing glycemic control gradually is suggested if diabetes is newly diagnosed, to prevent paradoxical worsening of neuropathic symptoms with rapid HbA1c reduction 3
Managing cardiovascular risk factors, such as blood pressure and lipids, is recommended as these contribute to neuropathy progression 1, 3

The American Diabetes Association recommends performing annual 10-g monofilament testing to monitor for loss of protective sensation 1, 3, 6
Educating patients on daily foot inspection for cuts, blisters, or pressure areas is suggested 3
Recommending protective footwear with adequate cushioning and proper fit is recommended 3
Arranging podiatry referral for regular foot care in patients with sensory loss is suggested 3

The American Academy of Neurology recommends assessing medication response objectively at 2-4 weeks, as adverse effects are common and serious complications can occur 1, 3
Performing annual comprehensive neuropathy assessment, including sensory testing and foot examination, is suggested 1, 3